Page last updated: 2024-12-11
n(4)-oleylcytosine arabinoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6441229 |
MeSH ID | M0179216 |
Synonyms (5)
Synonym |
---|
n(4)-oleylcytosine arabinoside |
1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-[[(z)-octadec-9-enyl]amino]pyrimidin-2-one |
(z)-1-beta-d-arabinofuranosyl-4-(9-otadecenylamino)-2(1h)-pyrimidinone |
2(1h)-pyrimidinone, 1-beta-d-arabinofuranosyl-4-(9-otadecenylamino)-, (z)- |
130252-71-0 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" The drug was administered intravenously and orally to ICR mice to assess its pharmacokinetic parameters in plasma and whole blood." | ( Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. Hänseler, E; Rentsch, KM; Schott, H; Schwendener, RA, 1997) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (40.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.99) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (10.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |